Company Interview / Racing ahead: successful trial & board revamp at Race Oncology

Dr Daniel Tillett from Race Oncology shares exciting developments about the company. Race Oncology's recent key leukaemia drug trial in Israel has achieved its goals despite challenges. Daniel reveals the firm's financial strength, noting funding secured until 2028, bolstered by $20 million from tax rebates.

Dr Tillett also highlights changes in the leadership team, aiming for a streamlined, focused board. The next phase involves launching a trial in Australia, New Zealand, Hong Kong, and South Korea. The trial explores cardio-protective aspects of their anti-cancer drug and could set a pivotal milestone for the company's success.

He discusses expanding global trial locations to ensure comprehensive data for drug approval in both US and China—a key strategy in today's biotech landscape. Dr Tillett emphasises the impact of the $20 million tax rebate, allowing for an accelerated R&D programme and extensive international trials, enhancing the company's potential reach.